Merck KGaA Fertility Business And Mavenclad Held Back By COVID-19 But Recovery Signs
Candidate Anti-COVID Toll-like Receptor Inhibitor Starts Phase II
Merck KGaA’s pharmaceutical sales were adversely affected by the COVID-19 pandemic in the second quarter, but the Process Solutions part of its life sciences division, products from which support vaccine developers, had a good quarter, and a potential dual Toll-like receptor inhibitor, M5049, entered Phase II.
